Table D13. Medication adherence outcomes 5

| Author, Year  Trial Name | Medication Adherence Outcome 5 | Description of Timing of Measurement of Adherence Outcome 5 | Data Source | N | Results |
| --- | --- | --- | --- | --- | --- |
| Hoffman et al., 200318  NA | Percent adherence using HEDIS guidelines, at 6 months | Measured once at 6 months; adherence defined as a total of 51 gap days since beginning treatment (days 1-180) | PRD | G1: 4889  G2: 4665 | G1: 31.5  G2: 29.4  95% CI, NR  p: < 0.05 |
| Katon et al., 199625  NA | A dosage of antidepressant medication for at least 90 days at or above lowest dosage recommended by AHCPR guidelines | NR | PRD | G1: 76  G2: NS | Major Depression Group, for at least 30 days (% adherent)  G1: 62.1%  G2: 54.6%  p=.55  Minor Depression Group, for at least 30 days (% adherent)  G1: 69.6%  G2: 39.5%  p=0.08 |
| Montori et al., 201135  NA | Started bisphosphonates | Measured at baseline | PRD | G1: 52  G2: 48 | Total  G1: 44%  G2: 40%  95% CI, NR  p: NR  <10% Risk Category  G1: 50%  G2: 25%  95% CI, NR  p: NR  10-30% Risk Category  G1: 45%  G2: 45%  95% CI, NR  p: NR  >30% Risk Category  G1: 40%  G2: 33%  95% CI, NR  p: NR |
| Murray et al., 200736  NA | Refill adherence: Medication possession ratio (meds received relative to meds prescribed) | Results calculated for 1 yr, incorporating the 9 month intervention and 3 month post-intervention period; Presume that since refills were every 2 months, there were 6 measurements every 2 months | PRD | G1: NR  G2: NR | G1: 109.4%  G2: 105.2%  95% CI, NR  Difference: 4.2%  p: 0.007 |
| Pyne et al., 201141  HIV Translating Initiatives for Depression Into Effective Solutions (HITIDES) | Antidepressant prescription rates (of providers) at 6 months | Not clear whether self-report or other method. 3 measurements taken: baseline, 6-month and 12-months. | Other | G1: 72/108 (66.7)  G2: 78/115 (67.8) | G1: 72/108 (66.7)  G2: 78/115 (67.8)  OR: 0.89 (0.49 to 1.78); adjusted OR; 0.89 (0.46 to 1.74) |
| Rich et al., 199642  NA | Number of patients with >90% medication compliance (unclear which method used to calculate) | 30 days +/- 2 days after discharge; 1 time; NA | Pill count | G1: 80  G2: 76 | G1: 45  G2: 26  95% CI, NR  p: 0.032 |
| Rudd et al., 200445  NA | Proportion of medications taken correctly among those on a >=2 times-daily dosing regimen | 1 day; daily ; 6 months | MEMS | NR | G1: 69% (34%)  G2: 49% (41%)  95% CI, NR  p: NR, not significant per text |
| Stacy et al., 200956  NA | 6 month point prevalence persistency (For those prescribed a lipid-lowering agent in the 7-12 month period prior to the index statin): subject being in possession of a statin at the end of the 180-day observation period | 6 months after baseline; 1 time; N/A | PRD | Overall N: 54  SG1: NR  SG2: NR | SG1: 66.7%  SG2: 37.0%  95% CI, NR  p: <0.05 |
| Vivian et al., 200258  NA | Compliance survey at 6 months: If answered yes to being away from home overnight in last 3 months, did you forget to take your medication when you were away from home overnight?, % who answered sometimes (2-3 times/wk) and always (>3 times/wk) | varied b/t groups; compliance measured in G1 at monthly visits, only measured at baseline and study end for G2 | Self-report | G1: 26  G2: 27 | G1: 15%  G2: 10%  95% CI, NR  p: 1.00 |
| Wilson et al., 201065  Better Outcomes of Asthma Treatment (BOAT) | Controller regimen anti-in?ammatory potency - acquisition of beclomethasone canister equivalents - year 2 | Measured as aggregate for entire year | PRD | G1: 204  G2: 202  G3: 204 | G1: 7.1  G3: 4.6  Group difference: 2.5  95% CI, 1.2 to 3.8  p= 0.0002  G1: 7.1  G2: 5.8;  Group difference: 1.4  95% CI, 0.04 to 2.7  p: 0.04  G2: 5.8  G3: 4.6  Group difference:1.1  95% CI, -0.18 to 2.4  p: >.05 |